Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

Recent & Breaking News (TSX:VRX)

Valeant Will Become Bausch Health Companies Inc.

PR Newswire May 8, 2018

Valeant Pharmaceuticals International Inc to Host Earnings Call

Accesswire May 8, 2018

Safirstein Metcalf LLP and HGT Law Remind Investors That a Shareholder Opt-out Lawsuit was Filed on Behalf of Retail Investors and Invite Investors to Contact the Firms - VRX

GlobeNewswire May 7, 2018

Bausch + Lomb Launches LUMIFY, The First And Only OTC Redness Relieving Eye Drop With Low-Dose Brimonidine

PR Newswire May 7, 2018

Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies

PR Newswire May 7, 2018

Steve Sosnick's Valeant Options Trade

Benzinga.com  May 4, 2018

Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference

PR Newswire May 3, 2018

Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection

PR Newswire May 2, 2018

Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication

PR Newswire May 2, 2018

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Benzinga.com  May 1, 2018

Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting

PR Newswire April 27, 2018

Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program

PR Newswire April 19, 2018

Arbitral Tribunal Decides In Favor Of Valeant In UCERIS Arbitration

PR Newswire April 12, 2018

Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery

PR Newswire April 11, 2018

Valeant And One Of Its Subsidiaries Announce Expiration And Final Settlement Date For Cash Tender Offers For Senior Notes

PR Newswire April 10, 2018

New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire April 9, 2018

Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII™ In The Journal of the American Academy of Dermatology

PR Newswire April 9, 2018

The Market In 5 Minutes: More Tariffs, Job Growth Slows, Longfin, Valeant And More

Benzinga.com  April 6, 2018

EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

GlobeNewswire April 6, 2018

Valeant Will Release First-Quarter 2018 Financial Results On May 8

PR Newswire April 6, 2018